Best Topics

Cadila Healthcare: Latest News

All news where Cadila Healthcare is mentioned

27.05.2021 / 06:37

Covid-19: Zydus seeks DCGI nod to undertake clinical trials for monoclonal antibodies cocktail

Covid infection.ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal antibodies.''Zydus Cadila today announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19. SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody based treatments have received emergency use authorization in mild COVID 19 in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization,'' Cadila Healthcare said in an exchange filing.Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19, it said.

India covid-19 patient

Zydus gets nod for to begin phase 3 trials of its Covid-19 vaccine in India

₹527.2 crore for the quarter ended December 2020 on account of robust sales in all segments.The company had posted a net profit of ₹373.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.Consolidated revenue of the company stood at ₹3,795.6 crore for the quarter under consideration.

India covid-19 vaccine

Zydus says P2 studies of Desidustat on Covid patients show positive results

Revenge of the lambs at the GabbatoirZydus Cadila, which is part of Cadila Healthcare, said in its regulatory filing: "Patients infected with COVID-19 have been reported to display signs of 'Hypoxia' leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators."The lung cells have been reported to develop extremely intense poisoning and inflammation, shortness of breath sets in and this can lead to acute respiratory distress syndrome (ARDS).

covid-19 patient

Cadila Healthcare June quarter net profit up 50% at Rs454 cr

₹3,639.9 crore for the quarter under consideration, as against ₹3,496.3 crore for the same period year ago NEW DELHI : Drug firm Cadila Healthcare on Wednesday reported a 49.53% rise in its consolidated net profit at ₹454 crore for the quarter ended June 30, mainly on account of robust sales in the pharmaceuticals segment.The company had posted a net profit of ₹303.6 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.Consolidated revenue from operations of the company stood at ₹3,639.9 crore for the quarter under consideration, as against ₹3,496.3 crore for the same period year ago, it added.The pharmaceuticals sales of the company rose to ₹3,102.5 crore for the quarter ended June this year,

city New Delhi India

COVID-19

United States	Cases: 46 252 513 Deaths: 750 423 Recovered: 0
India	Cases: 34 321 025 Deaths: 459 652 Recovered: 0
Brazil	Cases: 21 835 785 Deaths: 608 235 Recovered: 0
United Kingdom	Cases: 9 215 683 Deaths: 141 607 Recovered: 0
Russia	Cases: 8 494 589 Deaths: 237 619 Recovered: 0

Detail statistic

About Us

Covid-19.rehab - the latest news concerning the spread of the SARS-CoV-2 coronavirus (formerly 2019-nCoV), as well as the infectious disease that it causes COVID-19, in separate countries and in the world as a whole. Current news on the topic of coronavirus SARS-CoV-2. Quarantine, pandemic 2020, epidemic: what is it, when will it come to end, precautions and how to protect yourself from this disease. The most honest news, no fakes! To keep up with the latest news, stay tuned for updates on the site! Every day we will collect news and statistics on coronavirus from around the world for you to be aware of this topic.

Owner: SNOWLAND s.r.o.
Registration certificate 06691200
Address:
Snowland s.r.o.
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
Czech Republic